louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01655160: Effects and Mechanisms of Treatment Intensity of Mirror Therapy in Patients With Subacute Stroke
Official title: Effects and Mechanisms of Treatment Intensity of Mirror Therapy in Patients With Subacute Stroke: Outcomes in Brain and Movement Reorganization, Sensorimotor and Daily Functions, and Measures of Physiological Markers.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cerebrovascular Accident
Keywords: Stroke rehabilitation
Mirror therapy
Functional performance
Kinematic analysis
Functional magnetic resonance image
Motor recovery
Lead sponsor: Chang Gung Memorial Hospital
Sponsor class: OTHER
Collaborators: name: National Science and Technology Council, Taiwan
First posted: 2012-08-01
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study will evaluate the long-term benefits, optimal dose and mechanisms of mirror therapy and its effects on physiological markers.

Detailed description: This trial is to examine whether (1) the immediate effects of treatment intensity in MT would occur on sensorimotor impairments and functional performance in patients with subacute stroke; (2) the long-term benefits of treatment intensity in MT on functionality can persist for six months after treatment finished; and (3) the MT could result in cortical/movement reorganization as well as the changes in physiological markers.

Eligibility criteria: Inclusion Criteria:

* first episode of stroke in cortical regions
* time since stroke less than 3 months
* initial motor part of UE of FMA score ranging from 24 to 52
* no serious cognitive impairment

Exclusion Criteria:

* aphasia
* visual impairments
* major health problems or poor physical conditions
* currently participation in any other

Primary outcomes:
measure: Fugl-Meyer Assessment (FMA)
timeFrame: Baseline, change from baseline in FMA at 2 weeks, and change from baseline in FMA at 4 weeks
measure: Action Research Arm Test (ARAT)
timeFrame: Baseline, change of ARAT at 2 weeks, and change of ARAT at 4 weeks
measure: Motor Activity Log (MAL)
timeFrame: Baseline, change of MAL at 2 weeks, and change of MAL at 4 weeks
measure: ABILHAND Questionnaire
timeFrame: Baseline, change of ABILHAND Questionnaire at 2 weeks, and change of ABILHAND Questionnaire at 4 weeks
measure: Adelaide Activities Profile (AAP)
timeFrame: Baseline, change of AAP at 2 weeks, and change of AAP at 4 weeks
Secondary outcomes:
measure: Functional magnetic resonance imaging (fMRI)
timeFrame: Baseline and change of fMRI at 4 weeks
measure: Physiological marker measures
timeFrame: Baseline and change from baseline in physiological marker measures at 4 weeks
Other outcomes:
Locations:
city: Kwei-shan
country: Taiwan
facility: Chang Gung Memorial Hospital
state: Toayuan county
Study officials:
affiliation: Chang Gung University
name: Ching-yi Wu, ScD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03338660: Platelet Function With Various Storage Techniques
Official title: The Impact of Various Storage Techniques on Platelet Function
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Platelet Dysfunction Due to Drugs
Lead sponsor: Northwell Health
Sponsor class: OTHER
First posted: 2017-11-09
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: crossover study of various storage infusions techniques with each subject receiving various fluids aliquots.
Primary purpose: TREATMENT

Brief summary: Platelet function will be tested in individuals on antiplatelet medications to determine the optimal storage methodology.

Detailed description: Subjects will undergo administration of antiplatelet drugs and then will receive platelets stored in a variety of methods. Platelet function will be measured serially.

Eligibility criteria: Inclusion Criteria:

* Normal subjects

Exclusion Criteria:

* Pre existing antiplatelet drugs

Primary outcomes:
measure: Change in platelet function
timeFrame: 1 hour post-transfusion
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03455894: Evaluation of the DETECT'CHUTE CLINIBED Smart Carpet for Elderly People Fall Detection
Official title: Evaluation of the DETECT'CHUTE CLINIBED Smart Carpet for Elderly People Fall Detection
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Elderly People
Keywords: Fall detection
Smart carpet
Elderly people
Lead sponsor: University Hospital, Lille
Sponsor class: OTHER
First posted: 2018-03-07
Enrollment: 4
Sex: ALL
Minimum age (years): 70
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: DETECT'CHUTE CLINIBED is a smart carpet equipped with several sensors. Positioned at the foot of the bed, this system allows detecting i) patient fall out of the bed and ii) when patient is not back to bed after a certain time. When one of these two events is detected, the system then sends a short message syteme (SMS) and/or an email to the medical staff. The aim of this clinical study is to test the system ability to detect and transmit alarms for both those events.

In this clinical trial, the investigators will therefore test the alarms positive and negative predictive values for both the events.


Eligibility criteria: Inclusion Criteria:

* residents of the facility free to get up at night (without a barrier)
* residents may or may not be suffering from Alzheimer's disease or related illness.
* having fallen several times in the last 12 months and / or at risk of falling (time up and go test ≥ 20 seconds).

Exclusion Criteria:

* Subject under tutelage
* use of night barriers or other forms of physical restraint deemed necessary by the physician in charge of the unit care or the patient
* Refusal of the resident's relatives.

Primary outcomes:
measure: the positive predictive value of alerts
timeFrame: During 30 days
Secondary outcomes:
measure: the negative predictive value of alerts
timeFrame: During 30 days
measure: Time limit of the intervention of nurse
timeFrame: During 30 days
Other outcomes:
Locations:
city: Lille
country: France
facility: CHU
Study officials:
affiliation: University Hospital, Lille
name: François Puissieux, MD,PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04940494: Anal Incontinence After Obstetrical Anal Sphincter Injury
Official title: Incidence and Risk Factors for Anal Incontinence After Obstetrical Anal Sphincter Injury
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Obstetric Trauma
Anal Sphincter Injury
Anal Incontinence
Lead sponsor: University Hospital, Angers
Sponsor class: OTHER_GOV
First posted: 2021-06-25
Enrollment: 540
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All women that gave birth between 2005 January 1st and 2019 December 31th and that accept to respond to the survey

Brief summary: Obstetrical Anal Sphincter Injury is an identified risk factor for anal incontinence. The mechanisms and the risk factors for anal incontinence in Obstetrical Anal Sphincter Injury women are not well known.

Anal incontinence in such women is not well documented and probably underestimated. Cohort studies estimated that up to 53% of Obstetrical Anal Sphincter Injury women are incontinent but that most of them does not complain their doctor.


Eligibility criteria: Inclusion Criteria:

* Childbirth between 2005 January 1st and 2019 December 31th
* Obstetrical Anal Sphincter Injury -≥ 18 y

Exclusion Criteria:

* Patients' refusal
* lost of view or deceased
* anal incontinence before the Obstetrical Anal Sphincter Injury

Primary outcomes:
measure: anal incontinence
timeFrame: from the childbirth to the day of survey (2 to 16 years after childbirth)
Secondary outcomes:
measure: Incidence of anal incontinence
timeFrame: Incidence of anal incontinence the date of the survey (2 to 16 years after childbirth)
measure: cinetic of AI occurence
timeFrame: from the childbirth to the date of the survey (2 to 16 years after childbirth)
measure: Quality of life with fecal incontinence quality of life score
timeFrame: the date of the survey (2 to 16 years after childbirth)
measure: Expectation of the women in term of information
timeFrame: the date of the survey (2 to 16 years after childbirth)
Other outcomes:
Locations:
Study officials:
affiliation: University Hospital of Angers
name: Aurélien VENARA, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01915394: Respiratory Syncytial Virus Infection in Neonatal Intensive Care Units Throughout Turkey: Prospective Multicenter Study (TurkNICU-RSV Trial)
Official title: Management of Hospitalized Respiratory Syncytial Virus (RSV) Infected Patients in the Neonatal Intensive Care Unit (NICU) and Control of Epidemics; TurkNICU-RSV Study: A Multicentric, Prospective Trial
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Respiratory Syncytial Virus Infections
Infections, Epidemics
Keywords: Respiratory Syncytial Virus Infections
Epidemics
Neonatal Intensive Care Unit
Newborn infants
Lead sponsor: Ankara University
Sponsor class: OTHER
First posted: 2013-08-02
Enrollment: 250
Sex: ALL
Minimum age (years): 5
Maximum age (years): 90
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Hospitalized RSV infected newborn infants in the NICU.

Brief summary: The principle purpose of this multicenter trial is to determine the definition, timing and the percentage of nosocomial RSV epidemics throughout Turkey. In addition, secondary purpose of the trial is to determine the prevention strategies of further spread of Respiratory Syncytial Virus (RSV) in the neonatal intensive care unit (NICU).


Eligibility criteria: Inclusion Criteria:

* Confirmed RSV infection with either RSV-strip test or polymerase chain reaction (PCR).
* Admission to the NICU or hospitalized in the NICU between 1 October 2013 and 01 April 2014.

Exclusion Criteria:

* Refused informed consent

Primary outcomes:
measure: Hospitalized Respiratory Syncytial Virus infected Newborn in the Neonatal Intensive Care Units, and its relation with possible epidemics.
timeFrame: Patients will be followed during hospitalization, with expected average of 3 weeks
Secondary outcomes:
measure: Mortality
timeFrame: Patients will be followed during hospitalization, with expected average of 3 weeks
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Ankara University School of Medicine, Department of Pediatrics, Division of Neonatology
Study officials:
affiliation: Ankara University
name: Omer Erdeve, MD
role: STUDY_DIRECTOR
References:
citation: Oncel MY, Mutlu B, Kavurt S, Bas AY, Demirel N, Akyol M, Erdeve O, Dilmen U. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey. Turk J Pediatr. 2012 Jul-Aug;54(4):344-51.
citation: Dizdar EA, Aydemir C, Erdeve O, Sari FN, Oguz S, Uras N, Dilmen U. Respiratory syncytial virus outbreak defined by rapid screening in a neonatal intensive care unit. J Hosp Infect. 2010 Aug;75(4):292-4. doi: 10.1016/j.jhin.2010.01.013. Epub 2010 Mar 17.
citation: Alan S, Okulu E, Kilic A, Atasay B, Arsan S. Palivizumab use during respiratory syncytial virus outbreak in the neonatal intensive care unit. J Hosp Infect. 2012 Aug;81(4):292-3. doi: 10.1016/j.jhin.2012.05.011. Epub 2012 Jun 20. No abstract available.
Clinical trial NCT04703894: Tolerance and Acceptability Evaluation AYMES Cardiff
Official title: Tolerance and Acceptability Evaluation AYMES Cardiff
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Malnutrition
Lead sponsor: Aymes International Limited
Sponsor class: INDUSTRY
First posted: 2021-01-11
Enrollment: 17
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: To evaluate tolerance and acceptability of 'CARDIFF' in patients requiring supplementary oral nutritional support compared with currently available alternatives.

Detailed description: To evaluate tolerance and acceptability of 'CARDIFF' in patients requiring supplementary oral nutritional support compared with currently available alternatives, measuring outcomes of GI effects, Compliance, product preference, convenience etc.

To obtain data to support an ACBS submissions for 'CARDIFF' (to allow for prescription in the community at NHS expense).

Eligibility criteria: Inclusion Criteria:

* Male and female patients.
* ≥ 18 years of age.
* Patients of the intended target group (e.g. MUST score ≥ 1) with an anticipated period of nutritional support ≥ 30 days.
* Patient is able and willing to provide written informed consent.

Exclusion Criteria:

* Patients with medical or dietary contraindication to any feed ingredients.
* Patients requiring sole enteral tube feeding or parenteral nutrition.
* Patients with significant renal (requiring dialysis) or hepatic impairment (e.g. hepatitis.)
* Patients with dysphagia requiring levels 1, 2, 3 or 4 thickened fluids.
* Patients with uncontrolled inflammatory bowel disease or previous bowel resection with ongoing gastrointestinal symptoms.
* Patients for whom the investigator has concerns regarding the ability or willingness of the patient and or carer to comply with protocol requirements.
* Participation in any other studies involving investigational or marketed products concomitantly or within 2 weeks prior to entry into the study.

Primary outcomes:
measure: Gastro-Intestinal Tolerance when consuming AYMES CARDIFF
timeFrame: 30 days
Secondary outcomes:
measure: Acceptability and Palatability of Consuming the Nutritional Supplement: questionnaire
timeFrame: 30 days
measure: Compliance
timeFrame: 30 days
Other outcomes:
Locations:
city: Haywards Heath
country: United Kingdom
facility: AYMES International Ltd.
Study officials:
References:
Clinical trial NCT00941694: Asthma Self-Management in Older Adults
Official title: Asthma Self-Management in Older Adults
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Asthma
Aged
Keywords: asthma
aged
self care
Lead sponsor: University of Michigan
Sponsor class: OTHER
First posted: 2009-07-20
Enrollment: 70
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Asthma self-management is an effective way to improve the outcomes of patients with asthma. However, to be most effective these interventions should be targeted and designed toward a specific population or group. There is currently no asthma self-management intervention directed towards older adults. The hypothesis is that a 6-session asthma self-management intervention will improve the outcomes of older patients with asthma.


Eligibility criteria: Inclusion Criteria:: Age over 65, physician diagnosed asthma, need for daily asthma control medication, access to a telephone.

-

Exclusion Criteria: Smoking history greater than 40 pack years, current smoker, mental impairment that would preclude participation in the asthma self management program

-

Primary outcomes:
measure: Asthma Quality of Life Questionnaire
timeFrame: 3 months, 6 months, 1 year
Secondary outcomes:
measure: Asthma Control Questionnaire
timeFrame: 3 months, 6 months, 12 months
measure: Health Care Utilization
timeFrame: 3 months, 6 months, 12 months
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan
state: Michigan
Study officials:
affiliation: University of Michigan
name: Alan P Baptist, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00081094: Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer
Official title: Detection of Hepatocellular Carcinoma by Positron Emission Tomography With C-Acetate-11 and F-fluorodeoxyglucose-18
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Liver Cancer
Keywords: adult primary hepatocellular carcinoma
recurrent adult primary liver cancer
localized resectable adult primary liver cancer
Lead sponsor: Washington University School of Medicine
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2004-04-08
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: RATIONALE: Imaging procedures, such as carbon-11 acetate positron emission tomography (PET) and fludeoxyglucose F 18 PET, may improve the ability to detect hepatocellular carcinoma (liver cancer) and allow doctors to plan the most effective treatment.

PURPOSE: This clinical trial is studying how well carbon-11 acetate PET and fludeoxyglucose F 18 PET work in detecting cancer in patients with liver cancer.


Eligibility criteria: INCLUSION:

* Biopsy-proved HCC (stage I and II by conventional staging) or one or more of the following in a patient with clinically documented cirrhosis:
* AFP \> 200 mg/dL;
* A contrast-enhancing tumor mass (\>1 cm) by CT or MRI; or
* A tumor mass confirmed by arteriography.
* Patient must provide written informed consent and have completed conventional imaging and staging before initiation of PET imaging.

EXCLUSION:

* Pediatric patients under the age of 18 will be excluded from consideration from this study.
* Patients with a known prior malignancy (with the exception of basal cell carcinoma of the skin and carcinoma in situ of the cervix) within 5 years will be excluded from entry into the study. However, patients with a prior HCC thought to have a new primary or recurrent HCC are eligible.
* Pregnant and breastfeeding patients.
* Patients with poorly controlled diabetes mellitus (fasting blood glucose level \> 200 mg/dL)

Primary outcomes:
measure: Relative sensitivity and specificity of positron emission tomography (PET) scanning with carbon-11 acetate and fludeoxyglucose F 18
Secondary outcomes:
measure: Determine whether PET identifies additional sites of disease not detected by conventional imaging
measure: Obtain a preliminary estimate of the impact of PET on management of patients with HCC.
Other outcomes:
Locations:
city: St. Louis
country: United States
facility: Washington University School of Medicine
state: Missouri
Study officials:
affiliation: Washington University School of Medicine
name: William C. Chapman, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02154594: "The Efficacy of Acacia Catechu Mouthrinse as Antiplaque and Antigingivitis Agent in Fixed Orthodontic Appliance Patients.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Gingivitis
Keywords: Acacia
Chlorhexidine
Gingivitis
Orthodontic appliances.
Lead sponsor: Tatyasaheb Kore Dental College
Sponsor class: OTHER
First posted: 2014-06-03
Enrollment: 60
Sex: ALL
Minimum age (years): 15
Maximum age (years): 30
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: SUPPORTIVE_CARE

Brief summary: To study effect of acacia catechu a herbal extract;as antipaque and antigingivitis agent in patients with fixed orthodontic appliances.This study is a double blind randomized controlled trial.


Eligibility criteria: Inclusion Criteria:

* 60 patients in the age group of 15-30 yrs
* plaque induced gingivitis having fixed orthodontic appliance

Exclusion Criteria:

* seeking any type of antibacterial mouthwash within four weeks of commencement of study,
* history of any systemic disease, or past illness,
* mentally or physically handicapped,
* history of smoking, tobacco chewing, alcohol consumption,
* patients with periodontitis, pregnant and lactating women

Primary outcomes:
measure: Changes from baseline in Plaque index(PI)
timeFrame: 15 Days
Secondary outcomes:
measure: Changes from baseline in Gingival index(GI)
timeFrame: 15 Days
Other outcomes:
Locations:
city: Kolhapur
country: India
facility: Tatyasaheb Kore Dental College and Research Centre
state: Maharashtra
Study officials:
affiliation: Tatyasaheb Kore Dental College and Research Centre
name: Dr.Dhanashree R. Agarwal, B.D.S.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01776294: Prehypertension Among Medical Students in Visakhapatnam and Association With Cardiovascular Risk Factors
Official title: Prevalence of Prehypertension Among Medical Students and Association With Cardiovascular Risk Factors
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Prehypertension
Cardiovascular Risk Factors
Keywords: Prehypertension
Prevalence
Cardiovascular Risk Factors
Lead sponsor: Andhra Medical College
Sponsor class: OTHER_GOV
First posted: 2013-01-28
Enrollment: 275
Sex: ALL
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Graduate Medical Students

Brief summary: Student Investigator = Thakkallapalli Zeeshan Muzahid. The study aims to assess the prevalence of prehypertension among medical students of Andhra Medical College, Visakhapatnam, India and its association with other cardiovascular risk factors - overweight /obesity, diabetes, lipid profile.

Detailed description: 275 medical students will be studied and a history taken and examination done with special emphasis on recording of Blood Pressure, measurement of height and weight (\& Body Mass Index) and Waist Circumference in all. Glucose Tolerance Test and Fasting Lipid profile will be measured in a random selection of 30 prehypertensives and 30 normotensives.

Eligibility criteria: Inclusion Criteria:

* Medical Students studying MBBS (Bachelor of Medicine \& Bachelor of Surgery) in Andhra Medical College
* clinically healthy
* consent to participate in the study

Exclusion Criteria:

* known cardiovascular disease
* known hypertension
* using antihypertensive or other cardiovascular drugs
* using any drugs that can affect BP, weight, Blood sugar

Primary outcomes:
measure: prevalence of prehypertension among graduate medical students
timeFrame: two weeks
Secondary outcomes:
measure: correlation between blood pressure (Prehypertension) and BMI (obesity), Blood glucose, LDL level (dyslipidemia)
timeFrame: two weeks
Other outcomes:
Locations:
city: Visakhapatnam
country: India
facility: Andhra Medical College
state: Andhra Pradesh
Study officials:
affiliation: Andhra Medical College
name: Thakkallapalli Zeeshan Muzahid, MBBS
role: PRINCIPAL_INVESTIGATOR
References: